TABLE 3

Targeting ROS beyond oxidases: translation to the clinics

TargetDrug ClassCompound NamePathologyClinical Trial IdentifierCurrent Status
Nrf2-Keap1Nrf2 activatorSulforaphane (approved)Anthracycline-related cardiotoxicity in breast cancerNCT03934905Phase II
AgingNCT03730649, NCT03126539Phase II
SchizophreniaNCT02810964Phase II
Lung cancerNCT03232138Phase II
AutismNCT02677051Phase II
Bladder cancerNCT03517995Phase II
Clinical high-risk syndrome of psychosisNCT03932136Phase III
Subarachnoid hemorrhageNCT02614742Phase II
Bardoxolone (RTA402, CDDO-me)Chronic kidney diseasesNCT03749447Phase III
Pulmonary hypertensionNCT03068130Phase III
Autosomal dominant polycystic kidneyNCT03918447Phase III
Omaveloxolone (RTA 408)Friedreich ataxiaNCT02255435Phase II
DMF (approved)Multiple sclerosis
sGCsGC activatorCinaciguatHeart failureTerminatedTerminated
HMR1766Aortic valve stenosisNCT02481258Phase II
PainNCT00799656Phase II
sGC stimulatorAdempas, riociguat (approved)Pulmonary hypertension
VericiguatChronic heart failure with preserved ejection fractionNCT02861534Phase III
IW-1701Sickle cell diseaseNCT03285178Phase II
AchalasiaNCT02931565Phase II
Nelociguat (BAY60-4552)Male erectile dysfunctionNCT01168817Phase II
  • CDDO, 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate.